Catechol-O-methyltransferase breaks down levodopa. COMT inhibitors extend the clinical benefit of levodopa, and without levodopa COMT-inhibitors have no effect in PD. They typically do not require dose escalation and are thus simple to administer.
|
Presentation
|
Dosages in Milligrams |
Typical Treatment Regimens |
Indications for Usage |
|
Entacapone (Comtan®) |
200 |
200 mg 4–8 times daily (with each levodopa dose) |
Adjunct therapy for motor fluctuations |
|
Tolcapone (Tasmar®) |
100 |
100 mg up to 3 times daily |
Adjunct therapy for motor fluctuations (second-line due to side effects) |
|
Carbidopa/levodopa/entacapone (Stalevo®)
|
12.5/50/200, 25/100/200, 37.5/150/200, 50/200/200 |
150–1000 mg of levodopa total daily dose, dosed 2–3 times/day (divided 3-4 times) |
Replacement for carbidopa/levodopa, for motor fluctuations (benefit of entacapone) |
Ahlskog JE. Parkinson’s Disease Treatment Guide for Physicians. New York, NY: Oxford University Press; 2009.
Ahlskog JE. The Parkinson’s Disease Treatment Book: Partnering with Your Doctor to Get the Most from Your Medications. New York, NY: Oxford University Press; 2005.